Using in vitro and in vivo models in both immunocompetent and immunodeficient mice, we compared the efficacy of PI3K and SHP2 inhibitors alone or in combination, and measured their impact on primary tumor and lung metastatic growth, as well as on animal survival. Here, PIK3CA is linked to neoplasm.